

Publications 2010-2012

Title	Authors	Journal
Pharmacodynamics of the antibacterial effect and emergence of resistance to doripenem in <i>Pseudomonas aeruginosa</i> and <i>Acinetobacter baumannii</i> studied in an in vitro pharmacokinetic model	Bowker KE, Noel AR, Tomaselli SG, Elliott H, Macgowan AP .	Antimicrob Agents Chemother. 2012 Jun 19.
Bactericidal activity of multiple combinations of tigecycline and colistin against NDM-1-producing Enterobacteriaceae	Albur M, Noel A, Bowker K, MacGowan A	Antimicrob Agents Chemother. 2012 Jun;56(6):3441-3.
The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach	Mouton JW, Brown DF, Apfalter P, Cantón R, Giske CG, Ivanova M, MacGowan AP , Rodloff A, Soussy CJ, Steinbakk M, Kahlmeter G.	Clin Microbiol Infect. 2012 Mar;18(3):E37-45.
EUCAST expert rules in antimicrobial susceptibility testing	Leclercq R, Cantón R, Brown DF, Giske CG, Heisig P, Macgowan AP , Mouton JW, Nordmann P, Rodloff AC, Rossolini GM, Soussy CJ, Steinbakk M, Winstanley TG, Kahlmeter G.	Clin Microbiol Infect. 2011 Oct 21.
Revisiting Beta-lactams - PK/PD improves dosing of old antibiotics	MacGowan A.	Curr Opin Pharmacol. 2011 Oct;11(5):470-6.
Role of early intravenous to oral antibiotic switch therapy in the management of prosthetic hip infection treated with one- or two-stage replacement	Darley ES, Bannister GC, Blom AW, Macgowan AP , Jacobson SK, Alfouzan W.	J Antimicrob Chemother. 2011 Oct;66(10):2405-8.
Factors influencing the clinical outcome of methicillin-resistant <i>Staphylococcus aureus</i> bacteraemia	Albur MS, Bowker K, Weir I, MacGowan A.	Eur J Clin Microbiol Infect Dis. 2012 Mar;31(3):295-301.
Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective	Mouton JW, Ambrose PG, Canton R, Drusano GL, Harbarth S, MacGowan A , Theuretzbacher U, Turnidge J.	Drug Resist Updat. 2011 Apr;14(2):107-17.
Does laboratory antibiotic susceptibility reporting influence primary care prescribing in urinary tract infection and other infections?	McNulty CA, Lasseter GM, Charlett A, Lovering A, Howell-Jones R, Macgowan A , Thomas M.	J Antimicrob Chemother. 2011 Jun;66(6):1396-404.
Pharmacodynamics of razupenem (PZ601) studied in an in vitro pharmacokinetic model of infection	MacGowan AP , Noel A, Tomaselli S, Elliott H, Bowker K.	Antimicrob Agents Chemother. 2011 Apr;55(4):1436-42
Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection	MacGowan AP , Noel AR, Tomaselli S, Elliott HC, Bowker KE.	Antimicrob Agents Chemother. 2011

		Feb;55(2):867-73.
Tigecycline activity: low resistance rates but problematic disc breakpoints revealed by a multicentre sentinel survey in the UK	Hope R, Mushtaq S, James D, Pillana T, Warner M, Livermore DM; Tigecycline Susceptibility Testing Group.	J Antimicrob Chemother. 2010 Dec;65(12):2602-9.
Use of intravenous co-trimoxazole to treat bacterial infection: analysis of 50 treatment episodes	Barton E, Macgowan AP.	J Chemother. 2010 Aug;22(4):267-9.
Analyses of teicoplanin concentrations from 1994 to 2006 from a UK assay service	Tobin CM, Lovering AM, Sweeney E, MacGowan AP.	J Antimicrob Chemother. 2010 Oct;65(10):2155-7
Harmonization of antimicrobial susceptibility testing breakpoints in Europe: implications for reporting intermediate susceptibility	Brown D, Macgowan A.	J Antimicrob Chemother. 2010 Feb;65(2):183-5.